United Therapeutics CORP Form 4 insider transactions

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on April 11 and 12, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on April 9 and 10, 2024.

Director Raymond Dwek executed share tracking awards and disposed of common stock of United Therapeutics Corp on April 8, 2024, according to a Form 4 filing.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 5th and 8th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on April 3rd and 4th, 2024, under a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 1st and 2nd, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 27 and 28, 2024, under a pre-arranged 10b5-1 trading plan.

Nilda Mesa, a director at United Therapeutics Corp, sold 325 shares of common stock on March 27, 2024, at a price of $237.8 per share.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed multiple sales of common stock on March 25 and 26, 2024, through a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 21 and 22, 2024, under a pre-arranged 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on March 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on March 19 and 20, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on March 15 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 11 and 12, 2024, under a pre-arranged 10b5-1 trading plan.

Director Judy D. Olian exercised stock options and sold shares of United Therapeutics Corp (UTHR) on March 12, 2024.

Director Tommy G Thompson exercised share tracking awards and sold shares of United Therapeutics Corp on March 11, 2024.

Katherine J. Klein, a director at United Therapeutics Corp, reported the exercise of share tracking awards and subsequent disposal of common stock on March 8, 2024.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on March 7th and 8th, 2024, under a pre-arranged 10b5-1 trading plan.

Director Tommy G Thompson reports the acquisition and disposal of United Therapeutics Corp stock and share tracking awards on March 8, 2024.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Richard Giltner executed a share tracking award and disposed of 10,000 shares of United Therapeutics Corp stock on March 6, 2024.

Director Tommy G. Thompson reports acquisition and disposal of United Therapeutics Corp shares, including transactions involving share tracking awards.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock on March 5th and 6th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director Tommy G. Thompson exercised share tracking awards and adjusted his holdings in United Therapeutics Corp. on March 1, 2024.